Herein, we report a case of BRAF V600_W604 deletion–insertion R‐positive stage IVA lung adenocarcinoma that was successfully treated with dabrafenib and trametinib, and the importance of comprehensive genomic profiling tests, even when initial companion diagnostics did not detect druggable oncogene alterations, are discussed. This evidence concerns the gene BRAF and lung adenocarcinoma.